DBV Technologies
DBVT | NASDAQ
$10.27
-$0.75 (-6.76%)
At close: Nov 16, 2026, 4:00 PM ET
$10.27
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 4:10 PM ET
-6.76%
(1D)No price chart data available for 1D timeframe.
Rating
28
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #851/1021 (Top 83%)
Key Statistics
Market Data
Market Cap $245.68M
1D Range
10.20 10.91
52W Range
8.87 24.54
Valuation (TTM)
PE -4.37
PB 1.65
EV/EBITDA -0.51
Valuation (NTM)
Forward PE N/A
Forward PEG 0.18
Price Target $48.00
Cash Flow
FCF Yield -109.0%
SBC Adj. FCF Yield -115.7%
SBC Impact -6.2%
Margins
Gross Margin -110.7%
Operating Margin -3687.1%
FCF Margin N/A
Growth (CAGR)
Revenue 3Y | 5Y -143.5% |
-23.7%
Dil EPS 3Y | 5Y -41.5% |
-20.1%
FCF 3Y | 5Y -50.2% |
-36.5%
Returns
ROA -98.3%
ROE -121.8%
ROIC -123.4%
Financial Health
Net Cash
$152.3M
Current Ratio 3.24
Interest Coverage 0.00
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
DBV Technologies S.A., a biopharmaceutical firm based in Montrouge, France, operates at the clinical stage, focusing on the research and development of epicutaneous immunotherapy solutions. Its flagsh...
Sector Healthcare
Industry Biotechnology
Employees 125
IPO Date Oct 22, 2014
Website www.dbv-technologies.com
Fiscal Year January - December
Latest News
No news articles available yet.
Earnings
Latest Earnings
Oct 28, 2026
EPS
-$0.7
Miss -16.67%
YoY:
-104.08% REV
$1.79M
Beat +220.00%
YoY:
-44.60%Next Earnings
Mar 25, 2027
EPS Est
Pro
Rev Est
Pro
Analyst Summary
# of Analysts
4
Consensus
Buy
Price Target
$48.00
Upside
+367.38%
Buy (4)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove DBVT